55583-59-0Relevant articles and documents
Triazolopyrimidines identified as reversible myeloperoxidase inhibitors
Duclos, Franck,Abell, Lynn M.,Harden, David G.,Pike, Kristen,Nowak, Kimberly,Locke, Gregory A.,Duke, Gerald J.,Liu, Xiaoqin,Fernando, Gayani,Shaw, Scott A.,Vokits, Benjamin P.,Wurtz, Nicholas R.,Viet, Andrew,Valente, Meriah N.,Stachura, Sylwia,Sleph, Paul,Khan, Javed A.,Gao, Ji,Dongre, Ashok R.,Zhao, Lei,Wexler, Ruth R.,Gordon, David A.,Kick, Ellen K.
supporting information, p. 2093 - 2099 (2017/11/22)
Myeloperoxidase, a mammalian peroxidase involved in the immune system as an anti-microbial first responder, can produce hypochlorous acid in response to invading pathogens. Myeloperoxidase has been implicated in several chronic pathological diseases due to the chronic production of hypochlorous acid, as well as other reactive radical species. A high throughput screen and triaging protocol was developed to identify a reversible inhibitor of myeloperoxidase toward the potential treatment of chronic diseases such as atherosclerosis. The identification and characterization of a reversible myeloperoxidase inhibitor, 7-(benzyloxy)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-amine is described.
Antiviral Activity of Novel Bicyclic Heterocycles
-
Paragraph 1123, (2013/07/31)
The present invention relates to compound of Formula I, II, III, or IV, and/or a pharmaceutical acceptable addition salt thereof and/or a stereoisomer thereof and/or a solvate thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R11, and R12 are as defined in the claim 1 or as described in detail in the description of the invention, and to the use of said compounds to treat or prevent viral infections and their use to manufacture a medicine to treat or prevent viral infections, particularly infections with RNA-viruses belonging to the family of the Retroviridae, the family of the Flaviviridae and the family of the Picornaviridae and more preferably infections with Human Immunodeficiency Virus 1 (HIV1), Human Immunodeficiency Virus 2 (HIV2), Hepatitis C virus (HCV), Dengue virus, and enteroviruses like Coxsackievirus, Rhinovirus and Poliovirus. The present invention also relates to pharmaceutical compositions of said compounds and the use of said pharmaceutical compositions to treat or prevent viral infections. The present invention further relates to the use of said compounds as biologically active ingredients, more specifically as medicaments for the treatment of viral disorders and pathologic conditions such as, but not limited to, viral infections with Human Immunodeficiency Virus 1 (HIV1), Human Immunodeficiency Virus 2 (HIV2), Hepatitis C virus (HCV), Dengue virus, and enteroviruses like Coxsackievirus, Rhinovirus and Poliovirus.
Discovery of 7- N -piperazinylthiazolo[5,4- d ]pyrimidine analogues as a novel class of immunosuppressive agents with in vivo biological activity
Jang, Mi-Yeon,Lin, Yuan,De Jonghe, Steven,Gao, Ling-Jie,Vanderhoydonck, Bart,Froeyen, Mathy,Rozenski, Jef,Herman, Jean,Louat, Thierry,Van Belle, Kristien,Waer, Mark,Herdewijn, Piet
experimental part, p. 655 - 668 (2011/03/22)
Herein we describe the synthesis and in vitro and in vivo activity of thiazolo[5,4-d]pyrimidines as a novel class of immunosuppressive agents, useful for preventing graft rejection after organ transplantation. This research resulted in the discovery of a series of compounds with potent activity in the mixed lymphocyte reaction (MLR) assay, which is well-known as the in vitro model for in vivo rejection after organ transplantation. The most potent congeners displayed IC50 values of less than 50 nM in this MLR assay and hence are equipotent to cyclosporin A, a clinically used immunosuppressive drug. One representative of this series was further evaluated in a preclinical animal model of organ transplantation and showed excellent in vivo efficacy. It validates these compounds as new promising immunosuppressive drugs.